First Time Loading...

Aarti Drugs Ltd
NSE:AARTIDRUGS

Watchlist Manager
Aarti Drugs Ltd Logo
Aarti Drugs Ltd
NSE:AARTIDRUGS
Watchlist
Price: 491.6 INR -0.78% Market Closed
Updated: May 23, 2024
Section:
 

Relative Value

The Relative Value of one AARTIDRUGS stock under the Base Case scenario is 543.47 INR. Compared to the current market price of 491.6 INR, Aarti Drugs Ltd is Undervalued by 10%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AARTIDRUGS Relative Value
Base Case
543.47 INR
Undervaluation 10%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.8
P/S
P/S
Price to Sales
1.8
vs History
39
vs Industry
57
Median 3Y
1.7
Median 5Y
1.7
Industry
2.5
Forward
1.2
More Details
26.4
P/E
P/E
Price to Earnings
26.4
vs History
15
vs Industry
19
Median 3Y
23.8
Median 5Y
23
Industry
23.5
Forward
12.6
More Details
12.6
P/OCF
P/OCF
Price to OCF
12.6
vs History
58
vs Industry
31
Median 3Y
40
Median 5Y
15.3
Industry
17.4
More Details
51.7
P/FCFE
P/FCFE
Price to FCFE
51.7
vs History
42
vs Industry
12
Median 3Y
63.8
Median 5Y
48.1
Industry
24.3
More Details
3.5
P/B
P/B
Price to Book Value
3.5
vs History
65
vs Industry
22
Median 3Y
3.9
Median 5Y
3.8
Industry
2.1
More Details
1.9
EV/S
EV/S
Enterprise Value to Sales
1.9
vs History
41
vs Industry
55
Median 3Y
1.9
Median 5Y
1.8
Industry
2.6
Forward
1.3
More Details
5.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
5.6
vs History
55
vs Industry
39
Median 3Y
6.1
Median 5Y
5.8
Industry
5.3
More Details
15.1
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
15.1
vs History
33
vs Industry
26
Median 3Y
14.3
Median 5Y
14.2
Industry
13.7
Forward
8.3
More Details
18
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
18
vs History
23
vs Industry
26
Median 3Y
17
Median 5Y
16.7
Industry
17.4
Forward
10.5
More Details
13.3
EV/OCF
EV/OCF
Enterprise Value to OCF
13.3
vs History
58
vs Industry
31
Median 3Y
41.3
Median 5Y
15.9
Industry
16.2
More Details
36
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
36
vs History
30
vs Industry
14
Median 3Y
35.6
Median 5Y
-57.3
Industry
18.6
More Details
2.4
EV/IC
EV/IC
Enterprise Value to IC
2.4
vs History
58
vs Industry
32
Median 3Y
2.6
Median 5Y
2.5
Industry
1.9
More Details

Multiples Across Competitors

AARTIDRUGS Competitors Multiples
Aarti Drugs Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Aarti Drugs Ltd
NSE:AARTIDRUGS
45.2B INR 1.8 26.4 15.1 18
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
771.7B USD 21.5 125.8 61.5 69.9
DK
Novo Nordisk A/S
CSE:NOVO B
4.2T DKK 17.1 46.7 34.8 38.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
365.4B USD 4.3 9.5 11.7 15.3
US
Merck & Co Inc
NYSE:MRK
333.6B USD 5.4 144.7 36 58.8
UK
AstraZeneca PLC
LSE:AZN
192.7B GBP 5.1 38.7 175 279.2
CH
Roche Holding AG
SIX:ROG
185.7B CHF 3.2 16.2 9.2 10.9
CH
Novartis AG
SIX:NOVN
181.7B CHF 3.4 11.3 8.6 12.6
US
Pfizer Inc
NYSE:PFE
164.2B USD 3 -530.4 12.9 20.8
P/E Multiple
Earnings Growth
IN
Aarti Drugs Ltd
NSE:AARTIDRUGS
Average P/E: 52.4
26.4
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
125.8
346%
DK
Novo Nordisk A/S
CSE:NOVO B
46.7
84%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
9.5
-21%
US
Merck & Co Inc
NYSE:MRK
144.7
7 453%
UK
AstraZeneca PLC
LSE:AZN
38.7
168%
CH
Roche Holding AG
SIX:ROG
16.2
26%
CH
Novartis AG
SIX:NOVN
11.3
15%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -530.4
680%

See Also

Summary
AARTIDRUGS intrinsic value, competitors valuation, and company profile.
DCF Valuation
AARTIDRUGS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AARTIDRUGS stock valuation using valuation multiples.
Wall Street Estimates
AARTIDRUGS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AARTIDRUGS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 140,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.